Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)
South Korea · Delayed Price · Currency is KRW 11,290
-210 (-1.83%)
At close: Jun 1, 2026
Ahn-Gook Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 16,268 | 7,481 | 16,845 | 1,290 | 6,875 | 3,939 |
Depreciation & Amortization | 8,952 | 8,778 | 7,698 | 5,023 | 4,930 | 4,507 |
Loss (Gain) From Sale of Assets | -25.97 | -46.41 | -13,216 | -17.13 | -28.25 | -138.65 |
Asset Writedown & Restructuring Costs | 2.75 | 2.75 | 219.98 | - | 37.78 | - |
Loss (Gain) From Sale of Investments | -1,409 | -989.18 | -229.34 | -920.69 | 889.36 | -2,033 |
Loss (Gain) on Equity Investments | 293.17 | 579.82 | -1,352 | 1,641 | 1,645 | -2,613 |
Provision & Write-off of Bad Debts | -266.39 | 76.64 | -83.27 | 757.97 | 129.7 | 171.68 |
Other Operating Activities | 3,382 | -269.03 | 8,165 | 4,747 | 5,478 | 8,724 |
Change in Accounts Receivable | 29,470 | 30,226 | 3,541 | -7,972 | -11,980 | -10,171 |
Change in Inventory | -9,664 | -8,710 | -10,008 | -12,861 | -4,497 | -3,969 |
Change in Accounts Payable | 2,236 | 3,505 | -4,931 | 2,569 | 2,528 | 1,090 |
Change in Other Net Operating Assets | 1,555 | 5,049 | -1,735 | 4,415 | -4,219 | 1,964 |
Operating Cash Flow | 50,794 | 45,683 | 4,914 | -1,328 | 1,788 | 1,472 |
Operating Cash Flow Growth | 145.21% | 829.63% | - | - | 21.49% | -86.84% |
Capital Expenditures | -9,150 | -8,465 | -75,887 | -5,474 | -2,931 | -4,035 |
Sale of Property, Plant & Equipment | 6 | 6 | 11,833 | 11,201 | 15.5 | 42.09 |
Cash Acquisitions | -2,224 | -2,224 | - | - | - | - |
Sale (Purchase) of Intangibles | -183.4 | -131.34 | -395.05 | -708.77 | -735.39 | -1,028 |
Investment in Securities | -4,336 | -1,584 | -10,938 | 12,167 | 9,960 | 4,931 |
Other Investing Activities | -0 | - | 0 | 0 | -0 | 62.75 |
Investing Cash Flow | -15,887 | -12,398 | -75,386 | 17,186 | 6,431 | 3,118 |
Long-Term Debt Issued | - | - | 60,000 | 10,000 | - | - |
Long-Term Debt Repaid | - | -5,244 | -301.93 | -12,593 | -662.99 | -889.69 |
Net Debt Issued (Repaid) | -264.25 | -5,244 | 59,698 | -2,593 | -662.99 | -889.69 |
Repurchase of Common Stock | - | - | - | - | -554 | -435.14 |
Dividends Paid | -5,001 | -5,001 | -2,500 | -2,500 | -2,511 | -2,521 |
Other Financing Activities | - | - | -0 | - | - | - |
Financing Cash Flow | -5,265 | -10,244 | 57,198 | -5,093 | -3,728 | -3,846 |
Foreign Exchange Rate Adjustments | 120.72 | 63.62 | 127.64 | 8.08 | 77.69 | 136.61 |
Net Cash Flow | 29,762 | 23,104 | -13,147 | 10,772 | 4,569 | 881.42 |
Free Cash Flow | 41,643 | 37,218 | -70,972 | -6,802 | -1,143 | -2,563 |
Free Cash Flow Growth | 373.83% | - | - | - | - | - |
Free Cash Flow Margin | 12.62% | 12.13% | -26.18% | -2.91% | -0.56% | -1.57% |
Free Cash Flow Per Share | 3665.76 | 3274.68 | -6243.89 | -598.47 | -100.42 | -223.77 |
Cash Interest Paid | 2,661 | 2,807 | 2,665 | 976.99 | 662.47 | 121.11 |
Cash Income Tax Paid | 4,062 | 5,461 | 652.73 | 2,921 | 713.85 | 101.29 |
Levered Free Cash Flow | 43,607 | 37,633 | -82,472 | 4,491 | 1,732 | -988.07 |
Unlevered Free Cash Flow | 45,259 | 39,355 | -80,595 | 4,581 | 1,832 | -915.05 |
Change in Working Capital | 23,597 | 30,070 | -13,134 | -13,849 | -18,168 | -11,086 |